Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis

Medicine and Dentistry

• Chronic Bronchitis 100%
• Cephem Derivative 100%
• Oral 100%
• Pathogen 60%
• Haemophilus influenzae 40%
• Pneumococcus 40%
• Staphylococcus Aureus 20%
• Erythromycin 20%
• Cefuroxime 20%
• Doxycycline 20%
• Antiinfective Agent 20%
• Trimethoprim/Sulfamethoxazole 20%
• Cephalosporin 20%
• Risk Stratification 20%
• Penicillinase 20%
• Infection 20%
• Moraxella catarrhalis 20%
• Oxacillin 20%
• Pneumococcal Pneumonia 20%
• Cefdinir 20%
• Cefprozil 20%
• Aminopenicillin 20%
• Cefditoren 20%
• Streptococcus Pneumonia 20%
• Penicillin 20%
• Randomized Clinical Trials 20%
• Macrolide 20%
• Cephalosporin Derivative 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Bronchitis 100%
• Cephem Derivative 100%
• Infectious Agent 75%
• Pneumonia 50%
• Haemophilus influenzae 50%
• Macrolide 25%
• Randomized Clinical Trial 25%
• Infection 25%
• Antiinfective Agent 25%
• Penicillinase 25%
• Cephalosporin Derivative 25%
• Cotrimoxazole 25%
• Cefdinir 25%
• Doxycycline 25%
• Staphylococcus Aureus 25%
• Streptococcus Pneumonia 25%
• Oxacillin 25%
• Penicillin 25%
• Erythromycin 25%
• Cefuroxime 25%
• Cephalosporin 25%
• Moraxella catarrhalis 25%
• Cefprozil 25%
• Aminopenicillin 25%
• Cefditoren 25%